Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RYR2 | Q92736 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8134685 | 0.83 | RYR2 (0.45) | RYR2GAAMAPTALDH1A1AKR1C3 | |
| SCHEMBL6641681 | 0.80 | KMT2A (0.44) | RYR2MAPTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL9869158 | 0.80 | HSD11B1 (0.36) | RYR2GAAMAPTALDH1A1KMT2A | |
| SCHEMBL9218692 | 0.77 | SRD5A1 (0.36) | SMN1; SMN2TDP1 | |
| SCHEMBL9220554 | 0.77 | MALT1 (0.45) | SMN1; SMN2NOTUM | |
| SCHEMBL29443025 | 0.76 | AKR1C3 (0.50) | GAAMAPTMCL1SMN1; SMN2AKR1C3 | |
| SCHEMBL289302 | 0.76 | AKR1C3 (0.50) | GAAMAPTMCL1SMN1; SMN2AKR1C3 | |
| SCHEMBL9219428 | 0.75 | FABP7 (0.39) | RYR2GAAMAPTALDH1A1MITF | |
| Hydrochloric Acid SCHEMBL1371854 | 0.74 | AKR1C3 (0.48) | GAAMAPTMCL1SMN1; SMN2AKR1C3 | |
| SCHEMBL7352952 | 0.74 | AKR1C3 (0.48) | GAAMAPTMCL1SMN1; SMN2AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11874601-B2 | Resist composition, method of forming resist pattern, compound, and acid diffusion-controlling agent | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-01-16 | — | — | US | disclosed |
| US-11874601-B2 | Resist composition, method of forming resist pattern, compound, and acid diffusion-controlling agent | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-01-16 | — | — | US | disclosed |
| US-20220011665-A1 | RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, COMPOUND, AND ACID DIFFUSION-CONTROLLING AGENT | TOKYO OHKA KOGYO CO., LTD. (JP) | 2022-01-13 | — | — | US | disclosed |
| US-20050010050-A1 | Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of COX-2-mediated disorders | G.D. SEARLE & CO. (US) | 2005-01-13 | — | — | US | disclosed |
| US-6822102-B2 | COMPOUNDS SUCH AS (2S,3R)-6,8-DICHLORO-3,4-DIHYDRO-2-(TRIFLUOROMETHYL)-2H-1-BENZOPYRAN-3 -CARBOXYLIC ACID, USED AS ANTIINFLAMMATORY, ANTIARTHRITIC, ANTICARCINOGENIC AGENTS OR ANALGESICS | PHARMACIA CORPORATION | 2004-11-23 | — | — | US | disclosed |
| EP-1274700-B1 | DIHYDROBENZOPYRANS, DIHYDROBENZOTHIOPYRANS, AND TETRAHYDROQUINOLINES FOR THE TREATMENT OF COX-2-MEDIATED DISORDERS | PHARMACIA CORP (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20030232844-A1 | Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2 mediated disorders | PHARMACIA CORPORATION | 2003-12-18 | — | — | US | disclosed |
| EP-1274700-A1 | DIHYDROBENZOPYRANS, DIHYDROBENZOTHIOPYRANS, AND TETRAHYDROQUINOLINES FOR THE TREATMENT OF COX-2-MEDIATED DISORDERS | Pharmacia Corporation (US) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001049675-A1 | DIHYDROBENZOPYRANS, DIHYDROBENZOTHIOPYRANS, AND TETRAHYDROQUINOLINES FOR THE TREATMENT OF COX-2-MEDIATED DISORDERS | PHARMACIA CORPORATION (US) | 2001-07-12 | — | — | WO | disclosed |
| EP-0389425-B1 | Benzotiopyranyl amines | CIBA GEIGY AG (CH) | 1995-04-26 | — | — | EP | disclosed |
| US-5155130-A | Lipoxygenase inhibitors | CIBA-GEIGY CORPORATION (US) | 1992-10-13 | — | — | US | disclosed |
| US-5071858-A | Antipsychotic benzothiopyranylamines | CIBA-GEIGY CORPORATION (US) | 1991-12-10 | — | — | US | disclosed |
| EP-0412939-A2 | Certain benzopyran and benzothiopyran derivatives | CIBA-GEIGY AG (CH) | 1991-02-13 | — | — | EP | disclosed |
| EP-0389425-A1 | Benzotiopyranyl amines | CIBA-GEIGY AG (CH) | 1990-09-26 | — | — | EP | disclosed |
| EP-0118685-A1 | Propene derivatives and their use as plant growth inhibitors | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1984-09-19 | — | — | EP | disclosed |
| EP-0117412-A1 | Propene derivatives and their use as plant growth inhibitors | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1984-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220011665-A1 | RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, COMPOUND, AND ACID DIFFUSION-CONTROLLING AGENT | MRPS23, MRPS22, SLC11A2 | RYR2 3094/4885GAA 4618/4885MAPT 4785/4885 |
| US-11874601-B2 | Resist composition, method of forming resist pattern, compound, and acid diffusion-controlling agent | MRPS23, MRPS22, SLC11A2 | RYR2 3139/4885GAA 4625/4885MAPT 4792/4885 |
| US-20050010050-A1 | Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of COX-2-mediated disorders | PTGS2, PTGES2, PTGER2 | RYR2 1370/4885GAA 1391/4885MAPT 3839/4885 |
| US-20030232844-A1 | Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2 mediated disorders | PTGS2, PTGS1, PTGES2 | RYR2 1268/4885GAA 1318/4885MAPT 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.